

First Closing of BioMedCredit AG at CHF 50 million

Basel, September 1, 2006

BioMedPartners today announced the first closing of BioMedCredit AG at a total committed capital of CHF 50 million. BioMedCredit AG is the first dedicated mezzanine financing fund in Switzerland providing growth and expansion capital to innovative small- und mid-size companies in the biotechnology, medical technology, diagnostics, pharmaceutical and healthcare industry. BioMedCredit AG will actively support about twenty high potential companies via specialized loans. The fund has a strong investor base and is targeting committed capital of about CHF 100 million in a subsequent closing later in 2006.

“We are very pleased of having been able to establish BioMedCredit AG in the current market environment” said Dr. Gerhard Ries, General Partner at BioMedPartners. He added: “We are confident that BioMedCredit is well positioned to fill the financing gap for “technology- and service-oriented” Biotech/Medtech/Life Sciences companies and to become one of the primary source for financing the growth of innovative small- and midsize healthcare companies in Switzerland.”

About BioMedPartners

BioMedCredit AG will be managed by Basel-based BioMedPartners, who is also managing BioMedinvest AG. Since its inception in 2003, BioMedPartners has invested in more than twelve early stage companies in the human healthcare sector, of which already three have successfully completed their IPO or have been acquired or merged with leading companies in the industry. Specific examples include the IPO of Arpida AG and the acquisition of Glycart Biotechnology AG by Hoffmann-La Roche, which represents one of the most successful transaction in the European Biotech industry ever. With more than CHF 150 million in capital under management and a strong management team with an extensive scientific and financial network, BioMedPartners has established itself among the leading early stage healthcare investors in the Alpine Rim region.

For further information, please contact:

BioMedPartners

Dr. Gerhard Ries, General Partner
Elisabethenstrasse 23
CH-4051 Basel

T: +41 61 270 3580

F: +41 61 270 3500

E: ries@biomedvc.com

W: www.biomedvc.com